Tags

Type your tag names separated by a space and hit enter

Salivary phosphate secretion in chronic kidney disease.
J Ren Nutr. 2008 Jan; 18(1):87-90.JR

Abstract

BACKGROUND

Hyperphosphatemia is an important contributor to cardiovascular calcification in chronic renal failure (CRF) patients. Cardiovascular calcifications are responsible for the high morbidity and mortality in patients undergoing hemodialysis (HD). Despite dietary phosphate reduction and treatment with phosphate binders, serum phosphorus level, as recommended by K/DOQI guidelines, is achieved only by 50% of dialysis patients. Thus it is necessary to identify other therapeutic approaches to reducing serum phosphate. Phosphate may be secreted in the saliva, which is then swallowed, and this provides a source of endogenous phosphate and thus contributes to the hyperphosphatemia in CRF.

PATIENTS AND INTERVENTION

This study evaluated salivary phosphate in 68 HD patients and 110 subjects with various degrees of CRF, compared with 30 healthy subjects. Saxon's test confirmed normal salivary secretion volume in all subjects. Salivary and serum phosphate and calcium and serum parathyroid hormone were measured.

RESULTS

Both HD and CRF patients had significantly higher salivary phosphate levels compared with healthy control subjects. In the latter group of patients, salivary phosphate correlated positively with serum creatinine (P < .0001) and the glomerular filtration rate (P < .0001).

CONCLUSIONS

These results suggest that the level of salivary phosphate may provide a better marker than serum phosphate for the initiation of treatment of hyperphosphatemia in CRF and HD patients. The results may also offer a new horizon in the therapy of hyperphosphatemia by establishing measures to bind salivary phosphate in the mouth, and before saliva is swallowed.

Authors+Show Affiliations

University of Messina, and Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy. visavica@tin.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18089451

Citation

Savica, Vincenzo, et al. "Salivary Phosphate Secretion in Chronic Kidney Disease." Journal of Renal Nutrition : the Official Journal of the Council On Renal Nutrition of the National Kidney Foundation, vol. 18, no. 1, 2008, pp. 87-90.
Savica V, Calò L, Santoro D, et al. Salivary phosphate secretion in chronic kidney disease. J Ren Nutr. 2008;18(1):87-90.
Savica, V., Calò, L., Santoro, D., Monardo, P., Granata, A., & Bellinghieri, G. (2008). Salivary phosphate secretion in chronic kidney disease. Journal of Renal Nutrition : the Official Journal of the Council On Renal Nutrition of the National Kidney Foundation, 18(1), 87-90.
Savica V, et al. Salivary Phosphate Secretion in Chronic Kidney Disease. J Ren Nutr. 2008;18(1):87-90. PubMed PMID: 18089451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Salivary phosphate secretion in chronic kidney disease. AU - Savica,Vincenzo, AU - Calò,Lorenzo, AU - Santoro,Domenico, AU - Monardo,Paolo, AU - Granata,Antonio, AU - Bellinghieri,Guido, PY - 2007/12/20/pubmed PY - 2008/3/8/medline PY - 2007/12/20/entrez SP - 87 EP - 90 JF - Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation JO - J Ren Nutr VL - 18 IS - 1 N2 - BACKGROUND: Hyperphosphatemia is an important contributor to cardiovascular calcification in chronic renal failure (CRF) patients. Cardiovascular calcifications are responsible for the high morbidity and mortality in patients undergoing hemodialysis (HD). Despite dietary phosphate reduction and treatment with phosphate binders, serum phosphorus level, as recommended by K/DOQI guidelines, is achieved only by 50% of dialysis patients. Thus it is necessary to identify other therapeutic approaches to reducing serum phosphate. Phosphate may be secreted in the saliva, which is then swallowed, and this provides a source of endogenous phosphate and thus contributes to the hyperphosphatemia in CRF. PATIENTS AND INTERVENTION: This study evaluated salivary phosphate in 68 HD patients and 110 subjects with various degrees of CRF, compared with 30 healthy subjects. Saxon's test confirmed normal salivary secretion volume in all subjects. Salivary and serum phosphate and calcium and serum parathyroid hormone were measured. RESULTS: Both HD and CRF patients had significantly higher salivary phosphate levels compared with healthy control subjects. In the latter group of patients, salivary phosphate correlated positively with serum creatinine (P < .0001) and the glomerular filtration rate (P < .0001). CONCLUSIONS: These results suggest that the level of salivary phosphate may provide a better marker than serum phosphate for the initiation of treatment of hyperphosphatemia in CRF and HD patients. The results may also offer a new horizon in the therapy of hyperphosphatemia by establishing measures to bind salivary phosphate in the mouth, and before saliva is swallowed. SN - 1532-8503 UR - https://www.unboundmedicine.com/medline/citation/18089451/Salivary_phosphate_secretion_in_chronic_kidney_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1051-2276(07)00236-1 DB - PRIME DP - Unbound Medicine ER -